Citius Net Income vs Begin Period Cash Flow Analysis

CTXR Stock

USD 3.06 0.21 6.42%

Citius Pharmaceuticals financial indicator trend analysis is way more than just evaluating Citius Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Citius Pharmaceuticals is a good investment. Please check the relationship between Citius Pharmaceuticals Net Income and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.

Net Income vs Begin Period Cash Flow

Net Income vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Citius Pharmaceuticals Net Income account and Begin Period Cash Flow. At this time, the significance of the direction appears to have pay attention.

The correlation between Citius Pharmaceuticals' Net Income and Begin Period Cash Flow is -0.88. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Citius Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Citius Pharmaceuticals' Net Income and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Citius Pharmaceuticals are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Net Income i.e., Citius Pharmaceuticals' Net Income and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.88

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Citius Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Citius Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Citius Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Citius Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.At this time, Citius Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 12/11/2024, Tax Provision is likely to grow to about 695.5 K, while Enterprise Value Over EBITDA is likely to drop (63.66).

Citius Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Retained Earnings Total Equity	Capital Surpluse	Other Stockholder Equity	Other Liab	Current Deferred Revenue	Non Current Assets Total	Other Assets	Long Term Debt
Total Assets		0.41	0.64	0.77	1.0	-0.88	-0.93	0.71	0.87	0.87	0.94	0.94	0.89	0.91	0.96	0.05	0.94	0.98	-0.94	0.98	0.97	0.62	0.51	0.98	-0.05	0.63
Short Long Term Debt Total	0.41		0.55	0.48	0.39	-0.44	-0.38	0.27	0.45	0.45	0.44	0.32	0.52	0.56	0.42	0.74	0.42	0.4	-0.43	0.39	0.37	0.5	0.5	0.39	0.57	0.49
Other Current Liab	0.64	0.55		0.84	0.62	-0.49	-0.64	0.55	0.52	0.52	0.66	0.56	0.64	0.71	0.53	0.49	0.65	0.54	-0.66	0.63	0.62	0.76	0.73	0.68	0.33	0.71
Total Current Liabilities	0.77	0.48	0.84		0.75	-0.49	-0.84	0.89	0.48	0.48	0.8	0.77	0.87	0.9	0.62	0.31	0.8	0.69	-0.82	0.83	0.83	0.78	0.68	0.84	0.16	0.8
Total Stockholder Equity	1.0	0.39	0.62	0.75		-0.9	-0.91	0.68	0.88	0.88	0.94	0.93	0.87	0.89	0.97	0.04	0.93	0.98	-0.93	0.97	0.96	0.61	0.5	0.98	-0.06	0.62
Net Debt	-0.88	-0.44	-0.49	-0.49	-0.9		0.7	-0.39	-0.99	-0.99	-0.75	-0.71	-0.69	-0.67	-0.97	-0.06	-0.72	-0.86	0.76	-0.79	-0.76	-0.47	-0.43	-0.78	-0.09	-0.45
Retained Earnings	-0.93	-0.38	-0.64	-0.84	-0.91	0.7		-0.84	-0.7	-0.7	-0.91	-0.96	-0.94	-0.95	-0.82	-0.03	-0.92	-0.91	0.99	-0.97	-0.98	-0.67	-0.55	-0.96	0.08	-0.66
Accounts Payable	0.71	0.27	0.55	0.89	0.68	-0.39	-0.84		0.38	0.38	0.7	0.76	0.88	0.85	0.55	0.02	0.72	0.66	-0.8	0.8	0.82	0.7	0.58	0.79	0.01	0.73
Cash	0.87	0.45	0.52	0.48	0.88	-0.99	-0.7	0.38		1.0	0.74	0.7	0.68	0.66	0.96	0.05	0.71	0.85	-0.76	0.78	0.75	0.48	0.45	0.77	0.09	0.44
Cash And Short Term Investments	0.87	0.45	0.52	0.48	0.88	-0.99	-0.7	0.38	1.0		0.74	0.7	0.68	0.66	0.96	0.05	0.71	0.85	-0.76	0.78	0.75	0.48	0.45	0.77	0.09	0.44
Common Stock Total Equity	0.94	0.44	0.66	0.8	0.94	-0.75	-0.91	0.7	0.74	0.74		0.96	0.86	0.93	0.87	0.19	1.0	0.96	-0.89	0.95	0.95	0.55	0.42	0.95	-0.02	0.56
Common Stock Shares Outstanding	0.94	0.32	0.56	0.77	0.93	-0.71	-0.96	0.76	0.7	0.7	0.96		0.89	0.93	0.85	0.02	0.97	0.96	-0.94	0.98	0.98	0.54	0.39	0.97	-0.18	0.55
Non Current Liabilities Total	0.89	0.52	0.64	0.87	0.87	-0.69	-0.94	0.88	0.68	0.68	0.86	0.89		0.96	0.79	0.11	0.86	0.86	-0.95	0.93	0.93	0.68	0.57	0.92	0.11	0.7
Total Liab	0.91	0.56	0.71	0.9	0.89	-0.67	-0.95	0.85	0.66	0.66	0.93	0.93	0.96		0.8	0.2	0.93	0.89	-0.94	0.95	0.95	0.68	0.56	0.95	0.04	0.7
Total Current Assets	0.96	0.42	0.53	0.62	0.97	-0.97	-0.82	0.55	0.96	0.96	0.87	0.85	0.79	0.8		0.05	0.86	0.95	-0.85	0.9	0.88	0.51	0.43	0.9	-0.01	0.51
Short Term Debt	0.05	0.74	0.49	0.31	0.04	-0.06	-0.03	0.02	0.05	0.05	0.19	0.02	0.11	0.2	0.05		0.17	0.03	-0.04	0.04	0.03	0.36	0.37	0.05	0.65	0.38
Common Stock	0.94	0.42	0.65	0.8	0.93	-0.72	-0.92	0.72	0.71	0.71	1.0	0.97	0.86	0.93	0.86	0.17		0.95	-0.89	0.95	0.96	0.55	0.41	0.95	-0.05	0.56
Net Tangible Assets	0.98	0.4	0.54	0.69	0.98	-0.86	-0.91	0.66	0.85	0.85	0.96	0.96	0.86	0.89	0.95	0.03	0.95		-0.91	0.97	0.96	0.51	0.39	0.96	-0.13	0.52
Retained Earnings Total Equity	-0.94	-0.43	-0.66	-0.82	-0.93	0.76	0.99	-0.8	-0.76	-0.76	-0.89	-0.94	-0.95	-0.94	-0.85	-0.04	-0.89	-0.91		-0.97	-0.96	-0.71	-0.6	-0.96	-0.01	-0.69
Capital Surpluse	0.98	0.39	0.63	0.83	0.97	-0.79	-0.97	0.8	0.78	0.78	0.95	0.98	0.93	0.95	0.9	0.04	0.95	0.97	-0.97		1.0	0.64	0.52	0.99	-0.09	0.66
Other Stockholder Equity	0.97	0.37	0.62	0.83	0.96	-0.76	-0.98	0.82	0.75	0.75	0.95	0.98	0.93	0.95	0.88	0.03	0.96	0.96	-0.96	1.0		0.64	0.5	0.99	-0.11	0.65
Other Liab	0.62	0.5	0.76	0.78	0.61	-0.47	-0.67	0.7	0.48	0.48	0.55	0.54	0.68	0.68	0.51	0.36	0.55	0.51	-0.71	0.64	0.64		0.98	0.67	0.43	0.98
Current Deferred Revenue	0.51	0.5	0.73	0.68	0.5	-0.43	-0.55	0.58	0.45	0.45	0.42	0.39	0.57	0.56	0.43	0.37	0.41	0.39	-0.6	0.52	0.5	0.98		0.54	0.51	0.94
Non Current Assets Total	0.98	0.39	0.68	0.84	0.98	-0.78	-0.96	0.79	0.77	0.77	0.95	0.97	0.92	0.95	0.9	0.05	0.95	0.96	-0.96	0.99	0.99	0.67	0.54		-0.07	0.68
Other Assets	-0.05	0.57	0.33	0.16	-0.06	-0.09	0.08	0.01	0.09	0.09	-0.02	-0.18	0.11	0.04	-0.01	0.65	-0.05	-0.13	-0.01	-0.09	-0.11	0.43	0.51	-0.07		0.42
Long Term Debt	0.63	0.49	0.71	0.8	0.62	-0.45	-0.66	0.73	0.44	0.44	0.56	0.55	0.7	0.7	0.51	0.38	0.56	0.52	-0.69	0.66	0.65	0.98	0.94	0.68	0.42

Click cells to compare fundamentals

Citius Pharmaceuticals Account Relationship Matchups

Citius Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	43.8M	142.4M	114.0M	103.6M	119.2M	125.1M
Short Long Term Debt Total	1.4M	855.5K	678.2K	481.2K	553.4K	476.4K
Other Current Liab	1.7M	2.4M	3.0M	2.6M	3.0M	1.7M
Total Current Liabilities	4.1M	4.0M	4.5M	5.8M	6.6M	7.0M
Total Stockholder Equity	33.7M	132.2M	102.8M	90.8M	104.5M	109.7M
Net Debt	(12.5M)	(69.2M)	(41.0M)	(26.0M)	(23.4M)	(22.2M)
Retained Earnings	(70.6M)	(96.0M)	(129.7M)	(162.2M)	(146.0M)	(138.7M)
Accounts Payable	1.9M	1.3M	1.2M	2.9M	3.4M	3.5M
Cash	13.9M	70.1M	41.7M	26.5M	30.5M	16.0M
Cash And Short Term Investments	13.9M	70.1M	41.7M	26.5M	30.5M	16.0M
Common Stock Total Equity	28.9K	55.6K	146.0K	146.2K	168.1K	176.6K
Common Stock Shares Outstanding	39.2M	108.6M	146.1M	151.3M	174.0M	182.7M
Liabilities And Stockholders Equity	43.8M	142.4M	114.0M	103.6M	119.2M	125.1M
Non Current Liabilities Total	6.0M	5.7M	6.0M	6.4M	7.4M	7.7M
Total Liab	10.1M	9.6M	10.6M	12.2M	14.0M	14.7M
Total Current Assets	14.0M	72.8M	44.6M	34.4M	39.5M	41.5M
Short Term Debt	491.0K	354.5K	394.0K	218.4K	251.1K	340.8K
Common Stock	55.6K	146.0K	146.2K	158.9K	182.7K	191.8K
Net Tangible Assets	(1.6M)	33.7M	132.2M	102.8M	118.2M	124.2M
Retained Earnings Total Equity	(55.8M)	(70.6M)	(96.0M)	(129.7M)	(116.7M)	(110.9M)
Capital Surpluse	80.2M	104.2M	228.1M	232.4M	267.2M	280.6M
Other Stockholder Equity	104.2M	228.1M	232.4M	252.9M	290.8M	305.4M
Non Current Assets Total	29.8M	69.6M	69.4M	69.2M	79.6M	83.6M
Other Current Assets	122.2K	2.7M	2.9M	7.9M	9.1M	9.5M
Property Plant Equipment	590.0	1.6K	7.0K	4.1K	4.7K	3.0K
Property Plant And Equipment Net	987.8K	829.9K	650.2K	455.9K	524.2K	403.2K
Property Plant And Equipment Gross	987.8K	829.9K	650.2K	455.9K	524.2K	403.2K
Net Invested Capital	34.0M	132.2M	102.8M	90.8M	104.5M	68.3M
Net Working Capital	9.9M	68.8M	40.0M	28.6M	32.9M	24.9M
Capital Stock	55.6K	146.0K	146.2K	158.9K	182.7K	101.2K

Pair Trading with Citius Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Citius Stock

0.77	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.76	LLY	Eli Lilly	Pair Corr

Moving against Citius Stock

0.86	BMY	Bristol Myers Squibb	Pair Corr
0.84	ESPR	Esperion Therapeutics	Pair Corr
0.75	CAH	Cardinal Health	Pair Corr
0.67	XAIR	Beyond Air	Pair Corr
0.65	GILD	Gilead Sciences	Pair Corr

The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.

The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Citius Stock Analysis

When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC